Aims To report estimates of the prevalence of diabetic retinopathy
Introduction
Diabetic retinopathy (DR) is the most common cause of visual loss in the working age population of the United Kingdom. 1, 2 The management of patients with DR forms a large and increasing proportion of hospital eye service (HES) activity in the United, 3 and the prevalence of diabetes is predicted to continue increasing over the next decades, 4 with a concomitant rise in DR.
The last decade has seen significant changes in the organisation of care for patients with DR, with the introduction of national screening programmes for DR in all four countries of the UK. 2, 3, [5] [6] [7] [8] However, little up-todate information is available on the number of patients seen for DR in the HES, the proportion with different grades of DR and maculopathy, the number undergoing laser photocoagulation or intravitreal therapy, and their clinical outcomes.
These data are required to establish national standards of care and to enable patients, ophthalmologists, and managers to benchmark their personal or local outcomes. They are also essential for the planning of health-care requirements in the future and for evidence-based commissioning of services. 9 In particular, the prevalence of centre-involving diabetic macular oedema (CIDMO) in the UK HES has important implications for clinicians and commissioners, given the recent licensing 10 and NICE approval 11 of ranibizumab for this indication.
The NHS Connecting for Health's 'Do Once and Share' programme defined detailed data sets to be collected within electronic medical record (EMR) systems, including the following ophthalmology data sets: Diabetic Eye Disease (DED-DOAS), the Cataract National Data set, and the Glaucoma Data set. 12 The Royal College of Ophthalmologists (RCOphth) is responsible for professional standards in the practice of ophthalmology for the benefit of the general public. 13 The National Ophthalmology Database (NOD) 14 has been created under its auspices to collate anonymised data collected as a by-product of routine clinical care using EMR. The database conforms to nationally agreedupon data standards, with the aim of providing highquality data for national audit, research, and revalidation of clinicians. This project builds on a series of studies where clinicians have pooled EMR data to update benchmark standards for cataract and vitreo-retinal surgery. [15] [16] [17] [18] [19] 
Aims
The primary aim of this study was to report estimates of the prevalence of each grade of DR and maculopathy for a large cohort of patients managed by the UK HES.
Materials and methods

Data extraction
Data were extracted till 30 November 2010 from 30 NHS trusts across the UK that use a single EMR system (Medisoft Ophthalmology, Medisoft Limited, Leeds, UK). The lead clinician and Caldicott Guardian (who oversees data protection) at each centre gave written approval for the data extraction. This study was conducted in accordance with the declaration of Helsinki and the UK's Data Protection Act.
DR structured assessments
A 'DR structured assessment' is defined as the documentation of the presence or absence of a specified minimum number of clinical signs of DR and maculopathy for each eye. When all mandatory fields are completed, an algorithm in the EMR system automatically calculates the grade of DR and maculopathy according to the Early Treatment of Diabetic Retinopathy Study (ETDRS) International 20 and NHS Diabetic Eye Screening Programme (DESP) 21 classifications of DR. The EMR's DR structured assessment module was progressively implemented at sites from 2006 onwards, and its completion is usually made compulsory in medical retina clinics for patients with diabetes. Whether CIDMO was present can be calculated based on an analysis of data items recorded for each eye in the macula 'retinal thickening' field of the structured assessment. All structured assessment results for eyes recorded as 'ocular prosthesis' or for which 'other pathology makes DR grading impossible/not relevant' were excluded from analysis.
Estimates of the proportions of eyes with each grade of DR and maculopathy per NHS year utilised the last structured assessment record in that year for each eye. Results per year are displayed according to the NHS year, which runs from 1 April to 31 March. Data based on the diabetic status (diabetic, not diabetic, or not recorded) were available from the 2003 NHS year onwards, and data from structured assessments were available from the 2007 NHS year onwards, when the EMR system incorporated the algorithms defined in the DED-DOAS project. This analysis reports results for the patients for whom data were recorded on the NOD from the 2007 NHS year till the completion of the initial data extraction in November 2010. Analysis was performed using STATA version 11 (StataCorp LP, College Station, TX, USA).
Results
Between 2007 and 2010, 307 538 patients from 30 NHS hospital trusts have had data aggregated on the NOD: 138 431 (45.0%) were male; 168 708 (54.9%) were female; and sex was not specified for 399 (0.1%). Ethnicity was not recorded for 194 324 (63.2%) patients. Among the 113 214 patients for whom it was recorded, 90.6% were Caucasian, 4.3% were Black, 3.3% were Asian, 0.5% were of mixed race, and 1.3% belonged to other ethnicities. The median age at the time of the patient's first record on the NOD was 72 years (interquartile range: 59-80 years; range: 0-110 years). Diabetic status was not recorded for 131 035 (42.6%) patients; 76 127 (24.8%) patients were recorded as diabetic; and 100 376 (32.6%) patients were not diabetic. The median age of patients recorded as diabetic at the time of their first record on the NOD was 68 years (interquartile range: 57-77 years; range: 4-108 years).
The proportion of patients seen in the HES who were recorded as having diabetes remained stable at 30.1% in the 2007 NHS year and 31.8% in the last complete NHS year (2009). This proportion was higher for men than women (around 35% versus 25% in 2009, respectively), consistently with the higher prevalence of diabetes among men in the UK population. 4 
DR structured assessments
A total of 48 570 eyes from 24 292 patients with diabetes had one or more structured assessments recorded. Data on 120 eyes were excluded from analysis owing to the recording of 'other pathology makes DR grading not relevant/impossible' or 'presence of an ocular prosthesis', leaving 48 450 eyes from 24 280 patients with structured assessments eligible for analysis. The proportion of patients with diabetes who had a structured assessment recorded increased from 50.7% in 2007 to 86.8% in 2010, and the number of sites using the DR structured assessment module of the EMR increased from 3 in 2007 to 18 in 2010.
ETDRS grades and CIDMO in the last structured assessment
Of the 48 450 eyes with structured assessment data at the time of their last record, 679 eyes had either DR or maculopathy that was not possible to grade. Of the remaining 47 771 eyes, 11 356 (23.8%) eyes had no DR, 21 986 (46.0%) had mild non-proliferative DR (NPDR), 6963 (14.6%) had moderate NPDR, 2380 (5.0%) had severe NPDR, and 5086 (10.6%) had proliferative DR (PDR).
Clinically significant macular oedema (CSMO) was present in 6664 (13.9%) eyes, with 3116 (6.5%) eyes having non-centre-involving CSMO and 3548 (7.4%) having CIDMO. There were more eyes with CIDMO than with non-centre-involving CSMO among eyes with PDR, severe NPDR, and moderate NPDR (Figure 1) .
Proportions of eyes with DR and maculopathy by year
During each year of the study period, the proportion of eyes per year with no DR, NPDR, and active or regressed PDR varied between 12.6% and 20.6%, 59.6% and 67.3%, and 18.3% and 20.9%, respectively (Figures 2 and 3) .
The proportion of eyes per year with DR but no macular oedema, macular oedema but no CSMO, CSMO but not centre-involving, CIDMO, and eyes that could not be graded for diabetic maculopathy ranged from 57.3% to 64.8%, 3.6% to 4.0%, 7.0% to 8.2%, 8.7% to 10.0%, and 0.6% to 1.2%, respectively ( Figure 4 ).
Discussion
This is the first major study in the UK to harness the benefits of EMR systems to collate and analyse data on the grades of DR, and in particular, to give an estimate of the prevalence of CIDMO in patients attending the HES. The data are likely to be representative of the whole UK HES as they were obtained from 30 NHS hospitals, 18 of which used the DR structured assessment module. The hospitals are widely scattered across the UK and serve populations that vary in terms of age structure, ethnic mix, prevalence of diabetes, and socio-economic deprivation. This is particularly useful, as heterogeneity may exist between different regions and countries within the UK, in terms of the proportions of people with different grades of DR and maculopathy seen in the HES. Potential reasons for this heterogeneity include differences in DR-screening protocols (for example, two fields in England versus one in Scotland, and variation in rates of mydriatic use), grading protocols, disease duration before diagnosis and screening, control of glycaemic and hypertensive factors, and screening inclusion/exclusion criteria. [5] [6] [7] [8] [22] [23] [24] However, it should be acknowledged that these data were obtained from one EMR supplier. This was because at the time of the data extraction, only one EMR supplier collected the nationally agreed-upon DED-DOAS data set.
It is possible that units at the forefront of implementing EMR systems may not be typical of all units. Furthermore, during the study period, the number of sites using the DR module increased from 3 to 18, and the collated data do not allow us to make any comment on the proportion of doctors in each department that routinely used the EMR. However, the robustness of the data is aided by the prospective collection of a standardised data set as a by-product of routine clinical care, and by evidence that the proportion of patients with diabetes seen in hospital eye departments who had a structured DR assessment performed grew substantially during the study period from 51% in 2007 to 87% in 2010. The study suggests that the management of patients with diabetes forms a significant component of ophthalmic activity in the UK, a situation that is likely to be mirrored in other developed countries.
The structured assessment of the presence or absence of the signs of DR conforming to the nationally agreedupon data set was made available within the EMR from 2007. Our data confirm that this facility is increasingly used when clinicians are assessing grades of DR and maculopathy, reflecting increased implementation, and usage of the module. Completion of this screening is usually made compulsory within medical retina clinics but is less frequently used when assessing patients with diabetes for ocular pathology unrelated to diabetes; hence, we would never expect completion of the structured assessment screening to approach 100%. If all mandatory fields are completed, an algorithm within the EMR automatically calculates the grade of DR and maculopathy according to the ETDRS classification, 20 ensuring standardisation of data collection. This allows a contemporary estimate of the prevalence of each grade of retinopathy and maculopathy in a large cohort of patients managed by the UK HES. Approximately 20% of eyes have no DR, 45% have mild NPDR, 14% have moderate NPDR, 5% have severe NPDR, 6% have active PDR, and 10% have stable-treated PDR. Almost 14% of eyes have CSMO and just over half of these eyes (7.4%) have CIDMO. The ETDRS grade 61 (later 63, that is, photocoagulation scars together with fibrosis but no active neovascularisation) has a text description within the DR structured assessment of 'stable-treated PDR' and is equivalent to the new NHS DESP grade of R3s; this provides the first estimate of the proportion of eyes that may be safe to return to annual screening (depending on the status of the fellow eye and maculae).
No studies have been published in the recent literature, to our knowledge, of the prevalence of DR or maculopathy in the UK HES. Existing UK studies generally report prevalence estimates at the population level (that is, all individuals with DM) or at entry into DR-screening programmes. One previous study, the national DR laser treatment audit of 1995, did examine types of maculopathy treated in the UK HES, 25 as well as features of PDR. 26 However, the maculopathy grades reported are not in line with current classification systems, and the audit study preceded the advent of optical coherence tomography (OCT), which makes meaningful comparison with our data difficult. In addition, the case mix of patients with diabetes managed by the HES has probably changed substantially since 1995, with an increase in the number of patients with DR, the introduction of screening programmes, the advent of OCT, and changes in laser design and treatment thresholds. 3 The absence of other UK HES studies makes comparison difficult. Prevalence data for DR and maculopathy at the population level have been reviewed previously for the UK 27 and recently across the globe. 28 For the UK, the prevalence of any grade of DR in the Caucasian diabetic population has been estimated to be between 17% and 41%, and between 1% and 8% for PDR. [29] [30] [31] [32] [33] [34] [35] Another UK study reported DR prevalence to be 36% among white Europeans versus 45% among South Asians. 36 Worldwide, the prevalence of any grade of DR (among people with diabetes aged 20-79 years) has been estimated to be 35%, and that of PDR to be 7%. 37 Again, no studies have been published, to our knowledge, of the prevalence of CIDMO either in the UK HES or in other Western countries. As above, existing UK studies have reported prevalence estimates for all diabetic macular oedema (DMO) and/or CSMO at the population level. The prevalence of DMO in the UK diabetic population was reported to be 6% among white Europeans and 12% among South Asians. 36 For CSMO, the UK prevalence has been estimated to be 6% (in an inner city setting), though this study involved biomicroscopy, not OCT. 35 Importantly, epidemiological models have suggested that the number of patients with DMO in the UK will increase in future from 188 000 (2010) to 236 000 (2020). 38 Our study also provides estimates of the prevalence of CIDMO and CSMO for a given grade of DR among patients seen in the UK HES (see Figure 1) . For example, 14% of eyes with mild NPDR, 24% of eyes with moderate NPDR, 31% of eyes with severe NPDR, and 22% of eyes with PDR also had CSMO (whether or not centre-involving). No previous studies have published similar data, though two studies have reported DMO prevalence figures by grade of DR. The large Wisconsin study in the USA reported in 1984 that the prevalence of DMO was 3% (diabetes duration: 0-14 years) or 6% (Z15 years) in mild NPDR, 37% (0-14 years) or 63% (Z15 years) in moderate/severe NPDR, and 73% (0-14 years) or 74% (Z15 years) in PDR. 39 The figures in our study are higher for mild NPDR (14% versus 3-6%) because individuals with mild NPDR at screening will only be referred to the UK HES in the presence of significant maculopathy. However, our figures for PDR (22% versus 73-74%) may be much lower because we are considering only CSMO, rather than all DMO, and perhaps because of better control of glycaemic and hypertensive factors, earlier treatment of PDR, and the impact of screening. More recently, a Japanese study also found a significant correlation between the severity of DMO and the DR grade. 40 In their report, 28% of patients with mild/moderate NPDR, 67% with severe NPDR, and 51% with PDR also had DMO. However, some caution is required in attempting to compare figures between these reports: these studies were conducted in different countries at different periods, that is, with different genetic and environmental health determinants. Inclusion and exclusion criteria for the study populations were also different, as were technologies and drugs available for the detection and treatment of DR and maculopathy.
The information presented in this study provides an evidence base for commissioners, clinicians, and managers when planning appropriate allocation of workforce and resources for local and national diabetic eye services, as well as for the pharmaceutical industry. 9 In particular, these data are useful for calculating the proportion of patients with diabetes seen in the HES who are likely to require pan-retinal photocoagulation, macular laser, and/or intravitreal anti-VEGF therapy, as well as diagnostic tests such as fundal photography, OCT imaging, and fluorescein angiography. 3 It may be difficult to extrapolate our prevalence data on each grade of DR within the HES to the whole UK population with diabetes as there are few reliable data on the proportion of patients with diabetes that is seen within the HES. A very approximate estimate of 10% might be obtained from the Department of Health screening data, as 2 192 772 people were offered DR screening and 224 711 were excluded from screening in the third quarter of 2012-13; 41 the majority of those excluded would be expected to be those under the HES, but this figure may not be accurate as people may be excluded for other reasons. The total number of people with diabetes (diagnosed and undiagnosed) in the UK was estimated to be 3.8 million in 2011; according to this model, the number was predicted to rise to 5 million by 2025. 4 Importantly, this projected increase is expected to be accompanied by an increase in the number of patients with diabetic complications, including DR. 29 Prevalence figures are approximately three times higher in the NOD hospital data than wholepopulation estimates, reflecting the fact that more advanced grades of retinopathy are managed by the HES. The prevalence of any grade of DR was around 80% in our study (among patients undergoing a DR structured assessment), compared with 20-40% in population studies of patients with diabetes. PDR prevalence was around 20% and CSMO prevalence was around 18%, compared with 1-8% and 6%, respectively, in the population. [29] [30] [31] [32] [33] [34] [35] It is also difficult to make international comparisons for hospital DR prevalence data, as each country's health system has a different approach to thresholds for referral; hence, the proportion of patients with diabetes managed by the HES will be different from the proportion managed via primary care. The proportions of patients with DR managed by the UK HES should in theory be more consistent, as national screening programmes have been implemented to invite the whole UK population of patients with diabetes for screening and to refer to the HES only those with potentially sight-threatening retinopathy. However, some heterogeneity in referral rates between countries and regions may exist in the UK (as described above), though this may be reduced in future with the introduction of a common DESP pathway.
In conclusion, we have used the NOD to generate prevalence data on the grades of retinopathy and maculopathy for a large cohort of patients with diabetes managed by the HES in the UK. This sample is large and is likely to be broadly representative of those patients seen in UK NHS ophthalmology departments. These results have important implications for patients and clinicians, as well as managers and commissioners, of diabetic eye services, particularly when planning anti-VEGF services for eyes with CIDMO.
Summary
What was known before K The management of patients with diabetic retinopathy forms an important part of hospital eye service activity in the United Kingdom.
What this study adds K The UK National Ophthalmology Database is capable of collating standardised electronic medical record data on diabetic retinopathy and maculopathy from many hospital trusts.
K This can be used to generate clinically relevant information that is representative of the UK hospital eye service.
K Of people assessed for diabetic retinopathy in the UK hospital eye service, almost 10% of eyes have centreinvolving diabetic macular oedema, and around 20% have proliferative disease.
Conflict of interest
RL Johnston is the medical director of Medisoft Limited, which developed the electronic medical record from which data were extracted for the first iteration of the National Ophthalmology Database, but no funding was provided by the company for this study. TDL Keenan has consulted for Alimera Sciences and received compensation.
